Synovus Financial Corp Alaunos Therapeutics, Inc. Transaction History

Synovus Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$0.43 - $0.65 $322 - $487	-750 Reduced 1.8%	41,000 $20,000
Q4 2022 Feb 06, 2023	BUY	$0.5 - $261.0 $500 - $261,000	1,000 Added 2.45%	41,750 $27,000
Q3 2022 Oct 27, 2022	BUY	$1.04 - $322.5 $8,060 - $2.5 Million	7,750 Added 23.48%	40,750 $70,000
Q2 2022 Aug 10, 2022	SELL	$0.41 - $1.24 $15,579 - $47,120	-38,000 Reduced 53.52%	33,000 $41,000
Q1 2022 May 12, 2022	BUY	$0.62 - $1.17 $1,996 - $3,767	3,220 Added 4.75%	71,000 $46,000
Q3 2021 Nov 08, 2021	BUY	$1.44 - $2.73 $57,600 - $109,200	40,000 Added 143.99%	67,780 $124,000
Q3 2020 Nov 09, 2020	BUY	$2.39 - $3.43 $66,394 - $95,285	27,780 New	27,780 $70,000
Q2 2018 Aug 01, 2018	SELL	$3.02 - $4.94 $7,347 - $12,019	-2,433 Closed	0 $0
Q1 2018 May 07, 2018	BUY	$3.46 - $5.14 $8,418 - $12,505	2,433 New	2,433 $9,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Synovus Financial Corp with notifications on news.